Clinical trial
Testing of ADI-PEG in Hepatocellular Carcinoma
NCT00056992 · FDA Office of Orphan Products Development, U.S. Fed · Completed
Key facts
| NCT number | NCT00056992 |
|---|---|
| Title | Testing of ADI-PEG in Hepatocellular Carcinoma |
| Official title | Phase II Testing of ADI-PEG in Hepatocellular Carcinoma |
| Lead sponsor | FDA Office of Orphan Products Development, U.S. Fed |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Carcinoma, Hepatocellular |
| Intervention type | Drug |
| Interventions | ADI-PEG 20 |
| Enrollment | 34 |
| Start date | Sep 1, 2002 |
| Completion | Oct 1, 2003 |
| First posted | Mar 27, 2003 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: